[1]张慧峰,李 茉,许淑娣,等.拉帕替尼治疗HER2阳性局部晚期乳腺癌临床疗效研究[J].陕西医学杂志,2023,52(5):596-599.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.023]
　ZHANG Huifeng,LI Mo,XU Shudi,et al.Clinical efficacy of lapatinib in the treatment of HER2-positive locally advanced breast cancer[J].,2023,52(5):596-599.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.023]
点击复制

拉帕替尼治疗HER2阳性局部晚期乳腺癌临床疗效研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年5期
页码:
596-599
栏目:
药物与临床
出版日期:
2023-05-05

文章信息/Info

Title:
Clinical efficacy of lapatinib in the treatment of HER2-positive locally advanced breast cancer
作者:
张慧峰; 李 茉; 许淑娣; 白 跳
(西安市第九医院,陕西 西安 710054)
Author(s):
ZHANG Huifeng; LI Mo; XU Shudi; BAI Tiao
(Ninth Hospital of Xi'an,Xi'an 710054,China)
关键词:
乳腺癌;  单病灶;  手术治疗;  表柔比星;  曲妥珠单抗;  拉帕替尼
Keywords:
Breast cancer;  Single lesion;  Surgical treatment;  Epirubicin;  Trastuzumab;  Lapatinib
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2023.05.023
文献标志码:
A
摘要:
目的:探索新辅助化疗+双靶(帕妥珠单抗联合曲妥珠单抗)联合拉帕替尼治疗HER2阳性局部晚期乳腺癌的临床疗效。方法:选取96例单病灶HER2阳性局部乳腺癌患者,根据是否联合拉帕替尼治疗,将其分为联合组与对照组。联合组50例给予新辅助化疗+双靶联合拉帕替尼的综合治疗,对照组46例给予新辅助化疗+双靶治疗,比较两组患者的治疗效果。结果:治疗后,两组患者癌胚抗原(CEA)、糖类抗原15-3(CA15-3)、糖类抗原125(CA125)均较治疗前下降(均P<0.05),其中联合组各指标下降水平优于对照组(均P<0.05)。治疗后,两组患者IgA、IgG、IgM、CD3+、CD4+、CD4+/CD8+、NK细胞水平均高于治疗前,CD8+低于治疗前,其中联合组各指标优于对照组(均P<0.05)。治疗后,联合组总有效率为88.00%,对照组为69.56%,联合组优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。随访1年,联合组生活质量各项评分均高于对照组(均P<0.05)。结论:拉帕替尼辅助治疗局部晚期乳腺癌疗效显著。
Abstract:
Objective:To explore the clinical efficacy of neoadjuvant chemotherapy plus dual target(pertuzumab plus trastuzumab)combined with lapatinib in the treatment of patients with HER2-positive locally advanced breast cancer.Methods:A total of 96 patients with single-lesion HER2-positive locally breast cancer were selected and divided into the combination group and the control group according to whether they were treated with lapatinib or not.Fifty patients in the combined group were treated with neoadjuvant chemotherapy plus dual target drugs combined with lapatinib,and forty-six patients in the control group were treated with neoadjuvant chemotherapy plus dual target drugs therapy.The clinical efficacy of the two groups were compared.Results:After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3)and carbohydrate antigen 125(CA125)in the two groups were lower than those before treatment,and the decline levels of each index in the combined group were better than those in the control group(all P<0.05).After treatment,the levels of IgA,IgG,IgM,CD3+,CD4+,CD4+/CD8+ and NK cells in the two groups were higher than those before treatment,and CD8+ was lower than that before treatment,and the indexes in the combined group were better than those in the control group(all P<0.05).After treatment,the total effective rate was 88.00% in the combined group and 69.56% in the control group,and the combined group was better than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 1 year of follow-up,the scores of quality of life in the combined group were higher than those in the control group(all P<0.05).Conclusion:Lapatinib is effective for locally advanced breast cancer.

参考文献/References:

[1] Zavala VA,Serrano-Gomez SJ,Dutil J,et al.Genetic epidemiology of breast cancer in Latin America[J].Genes(Basel),2019,10(2):153.
[2] Lanta Q,Arveux P,Asselain B.Epidemiology and socio-cultural specificities of young women with breast cancer[J].Bull Cancer,2019,106(12):4-9.
[3] 李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916-920.
[4] 李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015-1018.
[5] 张发良,王 雪.紫杉醇联合拉帕替尼治疗HER2阳性晚期乳腺癌的疗效及对患者生活质量的影响[J].海南医学,2020,31(13):1652-1655.
[6] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013版)[J].中国癌症杂志,2013,32(8):637-684.
[7] Kitajima K,Miyoshi Y,Yamano T,et al.Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs.PERCIST 1.0[J].Nagoya J Med Sci,2018,80(2):183-197.
[8] 赵艳霞,马 兰,连臻强,等.2014年中国农村基于超声乳腺癌筛查多中心数据分析[J].中华肿瘤防治杂志,2020,27(3):172-178.
[9] 黄育北,高 鹰,戴弘季,等.中国城市女性乳腺癌筛查卫生经济学评价[J].中国肿瘤临床,2019,46(16):851-856.
[10] 张敏璐,彭 鹏,吴春晓,等.2008-2012年中国肿瘤登记地区女性乳腺癌发病和死亡分析[J].中华肿瘤杂志,2019,41(4):315-320.
[11] O'Shaughnessy J,Petrakova K,Sonke GS,et al.Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+,HER2- advanced breast cancer in the randomized MONALEESA-2 trial[J].Breast Cancer Res Treat,2018,168(1):127-134.
[12] Borges VF,Ferrario C,Aucoin N,et al.Tucatinib combined with ado-trastuzumab emtansine in advanced erbb2/her2-positive metastatic breast cancer:A phase 1b clinical trial[J].JAMA Oncol,2018,4(9):1214-1220.
[13] 李信娟,马 虎.以曲妥珠单抗为基础的HER2阳性乳腺癌双靶向治疗进展[J].中国肿瘤临床,2019,46(10):533-536.
[14] 闫文霞.将数据导入Excel表单用于曲妥珠单抗的用药安全管理[J].中国药物与临床,2019,19(23):4227-4229.
[15] 海 波,胡 倩,林颖欣,等.曲妥珠单抗联合拉帕替尼及多西紫杉醇一线治疗HER-2阳性晚期乳腺癌的安全性和有效性[J].现代肿瘤医学,2020,28(18):3159-3163.
[16] 黄文发,严 颖,张如艳,等.曲妥珠单抗和拉帕替尼在辅助曲妥珠单抗治疗后一线复发的HER2阳性晚期乳腺癌治疗中疗效的比较[J].肿瘤,2020,40(9):641-649.
[17] 李娜妮,刘 健,吴 凡,等.拉帕替尼联合白蛋白结合型紫杉醇治疗曲妥珠单抗治疗失败的HER2阳性乳腺癌的临床观察[J].中华内分泌外科杂志,2016,10(5):369-373.
[18] 冯秀梅,马 兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,42(11):1527-1530.
[19] 张小力,刘 芹,刘宝瑞.重楼皂苷抗肿瘤及调节肿瘤免疫微环境研究进展[J].陕西中医,2021,42(11):1640-1643.
[20] 秦海运,潘淑云,李 政,等.复方苦参注射液联合拉帕替尼治疗HER-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响[J].世界中医药,2018,13(6):1472-1476.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(5):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(5):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(5):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(5):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(5):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(5):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(5):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]

备注/Memo

备注/Memo:
基金项目:陕西省卫生健康科研基金资助项目(2018D060)
更新日期/Last Update: 2023-05-05